HOME >> MEDICINE >> NEWS
Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia

CHICAGO - An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cancer Center.

"Patients taking dasatinib achieve complete cytogenetic response - absence of the mutated protein that drives this disease - more rapidly than we've observed historically using the current front-line therapy. Side effects are very manageable," says Ehab L. Atallah, M.D., lead author of the study and a fellow in M. D. Anderson's Department of Leukemia. Atallah presented study results at the annual meeting of the American Society of Clinical Oncology in Chicago Saturday June 2nd, 2007. The clinical trial remains in progress with 35 patients enrolled.

Dasatinib, known commercially as Sprycel and produced by Bristol-Myers Squibb, was approved by the U.S. Food and Drug Administration a year ago for use by patients whose disease is unresponsive to or becomes resistant to the front-line therapy imatinib. Both drugs bind to and block a genetically flawed protein known as BCR-ABL, which causes the disease. Atallah explains that dasatinib binds to both forms BCR-ABL while imatinib blocks only one.

"Our hypothesis is that treating with dasatinib first will produce an earlier response, which may translate to a better overall survival," Atallah says. "We haven't proved that here, but these early results are encouraging."

Atallah and colleagues evaluated 35 patients who enrolled in the clinical trial between November 2005 and December 2006. Patients receive either 100 mg of dasatinib once daily or 50 mg twice daily.

Thirty four patients had been on the clinical trial for at least three months when Atallah and lead researcher Jorge Cortes, M.D., professor in the Department of Leukemia, evaluated their data. They found that 77 percent of pati
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
2-Jun-2007


Page: 1 2

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. Most seniors now have drug coverage, U-M study shows
3. Wireless technology shows promise in diagnosing pediatric intestinal disease
4. Study shows radiofrequency ablation highly effective in treating kidney tumors
5. Method shows promise for early detection of pancreatic cancer
6. Organic farming can feed the world, U-M study shows
7. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
8. Borderline personality disorder shows improvements with intensive psychotherapy
9. New drug shows promise in treatment of advanced thyroid cancer
10. Study shows Diachrome improves blood sugar control in people with type 2 diabetes
11. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/19/2019)... ... June 19, 2019 , ... ... progress made in 2018 by the Alliance and its partners. Under the theme ... voices from across the clean cooking sector, including an entrepreneur and manufacturer in ...
(Date:6/19/2019)... ... June 19, 2019 , ... Ovation® Fertility scientists have been invited to present ... Embryology (ESHRE) Annual Meeting in Vienna, June 23-26, 2019. , Ovation’s oral presentation ... both the Basic Science Award for Oral Presentation and the Fertility Society of Australia ...
(Date:6/18/2019)... LOUIS (PRWEB) , ... June 18, 2019 , ... ... quality and clinical outcomes, today announced Steve Einig has joined the organization in ... lead strategy and corporate initiatives around market engagement, marketing, strategic events and brand ...
(Date:6/14/2019)... (PRWEB) , ... June 14, 2019 , ... ... Pennsylvania Tempur-Pedic® Mattress & Pink Bag Event® scheduled for Saturday, July 13th. UBCF ... women, men and children directly impacted by breast cancer. This second event was ...
(Date:6/13/2019)... (PRWEB) , ... June 13, 2019 , ... Women’s Excellence in Obstetrics and Gynecology specializes ... conditions, some that may be difficult to diagnosis. Women’s Excellence handles routine and complicated ... cysts , Endometriosis , Heavy periods , Adhesions (scar ...
Breaking Medicine News(10 mins):
(Date:6/18/2019)... ... June 18, 2019 , ... ... facilities at 11500 W Olympic Blvd Suite 350 Los Angeles, CA, 90064, bringing ... research-backed methodologies. , MY Education Guru has created individual programs to assist ...
(Date:6/16/2019)... ... June 14, 2019 , ... AVIE! MedSpa and Laser Center is proud to ... and radiofrequency treatment for achieving dramatic improvements to the texture and tightness of skin ... stimulates the skin with tiny needles, spurring vibrant new collagen growth for a wide ...
(Date:6/14/2019)... ... June 14, 2019 , ... ... forecasting and analytics platform that helps Life Sciences Manufacturers accurately project their ... Life Sciences business leaders: accurate, automated forecasting of rebates and discounts and ...
Breaking Medicine Technology:
Cached News: